Before & after results

Bilaterial View 3D Color View 3D Grayscale View

Patient 1 Patient 2 Patient 3 Patient 4 Patient 5

Left Side Right Side

Primary Efficacy Endpoint:
Primary Efficacy Endpoint:
Two-grade or better improvement measured by both physician and patient rated photonumeric cellulite severity score assessments occurred in 7.6% (P=.006) of patients.³ Phase 3 subject images. Individual results may vary. After images were taken after third treatment with QWO.

Patient 1

Age: 43

FST: IV

BMI: 28.9

FST = Fitzpatrick skin type

BMI = Body mass index

Primary Efficacy Endpoint:
Two-grade or better improvement measured by both physician and patient rated photonumeric cellulite severity score assessments occurred in 7.6% (P=.006) of patients.³ Phase 3 subject images. Individual results may vary. After images were taken after third treatment with QWO.

Primary Efficacy Endpoint:
Primary Efficacy Endpoint:
Two-grade or better improvement measured by both physician and patient rated photonumeric cellulite severity score assessments occurred in 7.6% (P=.006) of patients.³ Phase 3 subject images. Individual results may vary. After images were taken after third treatment with QWO.

Patient 2

Age: 48

FST: III

BMI: 17.9

FST = Fitzpatrick skin type

BMI = Body mass index

Primary Efficacy Endpoint:
Two-grade or better improvement measured by both physician and patient rated photonumeric cellulite severity score assessments occurred in 7.6% (P=.006) of patients.³ Phase 3 subject images. Individual results may vary. After images were taken after third treatment with QWO.

Primary Efficacy Endpoint:
Primary Efficacy Endpoint:
Two-grade or better improvement measured by both physician and patient rated photonumeric cellulite severity score assessments occurred in 7.6% (P=.006) of patients.³ Phase 3 subject images. Individual results may vary. After images were taken after third treatment with QWO.

Patient 3

Age: 52

FST: II

BMI: 23.6

FST = Fitzpatrick skin type

BMI = Body mass index

Primary Efficacy Endpoint:
Two-grade or better improvement measured by both physician and patient rated photonumeric cellulite severity score assessments occurred in 7.6% (P=.006) of patients.³ Phase 3 subject images. Individual results may vary. After images were taken after third treatment with QWO.

Primary Efficacy Endpoint:
Actual patient. Photos are unretouched. Individual results may vary. After images were taken after third treatment with QWO.

Patient 4

Age: 47

FST: IV

BMI: 23.8

FST = Fitzpatrick skin type

BMI = Body mass index

Actual patient. Photos are unretouched. Individual results may vary. After images were taken after third treatment with QWO.

Primary Efficacy Endpoint:
Actual patient. Photos courtesy of China Battista, APN-BC. Photos are unretouched. Individual results may vary. After images were taken after third treatment with QWO.

Patient 5

Age: 47

FST: II

BMI: 22.0

FST = Fitzpatrick skin type

BMI = Body mass index

Actual patient. Photos courtesy of China Battista, APN-BC. Photos are unretouched. Individual results may vary. After images were taken after third treatment with QWO.

Sales representative with HCP

Sales representative with HCP

Are your patients appropriate for QWO?

Learn more about identifying appropriate candidates for QWO treatment.

Patient Selection

Ready to learn more about QWO?

Connect with us to receive more information and updates on QWO.

Let's Connect

Let's Connect

Indication

Qwo^® is indicated for the treatment of moderate to severe cellulite in the buttocks of adult women.

Important Safety Information for QWO

Contraindications

QWO is contraindicated in patients with a history of hypersensitivity to collagenase or to any of the excipients or the presence of infection at the injection sites.

Warnings and Precautions

Hypersensitivity Reactions

Serious hypersensitivity reactions including anaphylaxis have been reported with the use of collagenase clostridium histolyticum. If such a reaction occurs, further injection of QWO should be discontinued and appropriate medical therapy immediately instituted. Advise patients to seek immediate medical attention if they experience any symptoms of serious hypersensitivity reactions.

Injection Site Bruising

In clinical trials, 84% of subjects treated with QWO experienced injection site bruising. Subjects with coagulation disorders or using anticoagulant or antiplatelet medications (except those taking ≤150 mg aspirin daily) were excluded from participating in Trials 1 and 2.

QWO should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet (except those taking ≤150 mg aspirin daily) or anticoagulant therapy.

Substitution of Collagenase Products

QWO must not be substituted with other injectable collagenase products.

QWO is not intended for the treatment of Peyronie’s Disease or Dupuytren’s Contracture.

Adverse Reactions

In clinical trials, the most commonly reported adverse reactions in patients treated with QWO with an incidence ≥ 10% were at the injection site: bruising, pain, nodule and pruritus.

View Full Prescribing Information for QWO.